Pfizer to Buy Allergan in 160 Billion Dollar Deal
By HospiMedica International staff writers Posted on 06 Dec 2015 |
In the largest ever deal in the health care sector, Pfizer (New York, NY, USA) will buy Botox maker Allergan (Dublin, Ireland), in a deal worth USD 160 billion.
The inversion acquisition, which would create the world's largest pharmaceutical conglomerate and shift Pfizer's headquarters to Ireland, would also be the biggest-ever instance of a US company reincorporating overseas to lower its taxes, from about 25% to about 17%–18% within the year. The merger would also give Pfizer access to tens of billions of dollars that are outside the borders of the United States, allowing for more buybacks, dividend payments, and business development. The combined company would have annual sales of about USD 64 billion. The deal is expected to close in the second half of 2016.
The transaction was structured so that smaller, Ireland- based Allergan would buy Pfizer so as to avoid potential regulatory restrictions, although the combined company will be known as Pfizer and will continue to be led by CEO Ian Read. Allergan CEO Brent Saunders will become president and COO of the combined company, with oversight of all commercial businesses. The acquisition comes 18 months after an USD 118 billion bid to acquire AstraZeneca (London, United Kingdom) in a similar inversion failed due to stiff opposition from management and UK politicians.
“The proposed combination of Pfizer and Allergan will create a leading global pharmaceutical company with the strength to research, discover and deliver more medicines and therapies to more people around the world,” said Ian Read, Chairman and CEO of Pfizer. “Allergan's businesses align with and enhance Pfizer's businesses, creating best-in-class, sustainable, innovative and established businesses that are poised for growth.”
“The combination of Allergan and Pfizer is a highly strategic, value-enhancing transaction that brings together two biopharma powerhouses to change lives for the better,” said Brent Saunders, CEO of Allergan. “Joining forces with Pfizer matches our leading products in seven high-growth therapeutic areas and our robust R&D pipeline with Pfizer's leading innovative and established businesses, vast global footprint, and strength in discovery and development research to create a new biopharma leader.”
US President Barack Obama has called such inversion deals “unpatriotic” and has tried to crack down on the practice, and democratic presidential candidate Hillary Clinton has pledged to establish measures to prevent such deals. The merger was also criticized by rival democratic candidate Senator Bernie Sanders and Republican presidential candidate Donald Trump.
Related Links:
Pfizer
Allergan
AstraZeneca
The inversion acquisition, which would create the world's largest pharmaceutical conglomerate and shift Pfizer's headquarters to Ireland, would also be the biggest-ever instance of a US company reincorporating overseas to lower its taxes, from about 25% to about 17%–18% within the year. The merger would also give Pfizer access to tens of billions of dollars that are outside the borders of the United States, allowing for more buybacks, dividend payments, and business development. The combined company would have annual sales of about USD 64 billion. The deal is expected to close in the second half of 2016.
The transaction was structured so that smaller, Ireland- based Allergan would buy Pfizer so as to avoid potential regulatory restrictions, although the combined company will be known as Pfizer and will continue to be led by CEO Ian Read. Allergan CEO Brent Saunders will become president and COO of the combined company, with oversight of all commercial businesses. The acquisition comes 18 months after an USD 118 billion bid to acquire AstraZeneca (London, United Kingdom) in a similar inversion failed due to stiff opposition from management and UK politicians.
“The proposed combination of Pfizer and Allergan will create a leading global pharmaceutical company with the strength to research, discover and deliver more medicines and therapies to more people around the world,” said Ian Read, Chairman and CEO of Pfizer. “Allergan's businesses align with and enhance Pfizer's businesses, creating best-in-class, sustainable, innovative and established businesses that are poised for growth.”
“The combination of Allergan and Pfizer is a highly strategic, value-enhancing transaction that brings together two biopharma powerhouses to change lives for the better,” said Brent Saunders, CEO of Allergan. “Joining forces with Pfizer matches our leading products in seven high-growth therapeutic areas and our robust R&D pipeline with Pfizer's leading innovative and established businesses, vast global footprint, and strength in discovery and development research to create a new biopharma leader.”
US President Barack Obama has called such inversion deals “unpatriotic” and has tried to crack down on the practice, and democratic presidential candidate Hillary Clinton has pledged to establish measures to prevent such deals. The merger was also criticized by rival democratic candidate Senator Bernie Sanders and Republican presidential candidate Donald Trump.
Related Links:
Pfizer
Allergan
AstraZeneca
Latest Business News
- Johnson & Johnson Acquires Cardiovascular Medical Device Company Shockwave Medical
- Mindray to Acquire Chinese Medical Device Company APT Medical
- Olympus Acquires Korean GI Stent Maker Taewoong Medical
- Karl Storz Acquires British AI Specialist Innersight Labs
- Stryker to Acquire French Joint Replacement Company SERF SAS
- Medical Illumination Acquires Surgical Lighting Specialist Isolux
- 5G Remote-Controlled Robots to Enable Even Cross-Border Surgeries
- International Hospital Federation Announces 2023 IHF Award Winners
- Unprecedented AI Integration Transforming Surgery Landscape, Say Experts
- New WHO Guidelines to Revolutionize AI in Healthcare
- Getinge Acquires US-Based Medical Equipment Provider Healthmark Industries
- Global Surgical Lights Market Driven by Increasing Number of Procedures
- Global Capsule Endoscopy Market Driven by Demand for Accurate Diagnosis of Gastrointestinal Conditions
- Global OR Integration Market Driven by Need for Improved Workflow Efficiency and Productivity
- Global Endoscopy Devices Market Driven by Increasing Adoption of Endoscopes in Surgical Procedures
- Global Minimally Invasive Medical Devices Market Driven by Benefits of MIS Procedures